Communicating About Nicotine Reduction in Cigarettes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorGeorgia State University
About this trial
The goal of this clinical trial is to learn how a messaging campaign about reduced nicotine cigarettes and policy, combined with the use of very low nicotine cigarettes (VLNCs), affects smoking behavior and attitudes among adult smokers. The study also aims to assess the efficacy of the messages in different populations, including smokers with past-month serious psychological distress (SPD), low socioeconomic status (SES), and those in neither category.
The primary hypothesis is: exposure to messages in combination with VLNC use will lead to less cigarettes use compared to VLNCs without messages.
Researchers will compare: The effects of receiving VLNCs with messages (treatment group) to receiving VLNCs without messages (control group).
Participants will: Complete a baseline survey and be randomly assigned to one of two groups: treatment (VLNCs + messages) or control (VLNCs only). Attend weekly study visits for surveys, breath samples, and receive supply of VLNCs , either with or without the messaging campaign. Complete brief daily surveys through text messages.
Eligibility criteria
Qualifiers
Age 21+ years
Current smoker (self-report as having smoked 100 cigarettes in their lifetime and currently smoking on 27+ days out of past 30, expired breath carbon monoxide [CO] ≥6ppm to assess regular smoking)
Can speak, read, and write in English
Available for period of study
Disqualifiers
Pregnancy or lactation
Member of the same household as a study subject
Unwilling to use research cigarettes as part of the trial
Trial design
Treatments tested in this trial
- VLNC messages
- Control message
Treatment groups
1,230 Participants
are divided into 2 treatment groupsSponsors and collaborators
Georgia State University
Lead sponsor
Emory University
Collaborator
University of South Carolina
Collaborator
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov